Kazia Therapeutics Limited
KZIA
$13.16
-$0.67-4.85%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 13.50K | 13.20K | -- |
| Total Other Revenue | 30.20K | 30.10K | 565.20K | 553.50K | 7.30K |
| Total Revenue | 30.20K | 30.10K | 578.70K | 566.70K | 7.30K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 30.20K | 30.10K | 578.70K | 566.70K | 7.30K |
| SG&A Expenses | 2.81M | 2.80M | 1.16M | 1.13M | 1.66M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.45M | 4.43M | 2.13M | 2.09M | 3.06M |
| Operating Income | -4.42M | -4.40M | -1.55M | -1.52M | -3.05M |
| Income Before Tax | -4.12M | -4.11M | -3.80M | -3.72M | -3.45M |
| Income Tax Expenses | -- | -- | -515.80K | -505.10K | -44.20K |
| Earnings from Continuing Operations | -4.12M | -4.11M | -3.28M | -3.21M | -3.41M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.12M | -4.11M | -3.28M | -3.21M | -3.41M |
| EBIT | -4.42M | -4.40M | -1.55M | -1.52M | -3.05M |
| EBITDA | -4.26M | -4.25M | -1.40M | -1.33M | -2.75M |
| EPS Basic | -660.05 | -657.95 | -1.22K | -1.20K | -2.00K |
| Normalized Basic EPS | -0.83 | -0.82 | -0.79 | -0.77 | -2.72 |
| EPS Diluted | -660.45 | -658.35 | -1.22K | -1.20K | -2.00K |
| Normalized Diluted EPS | -0.83 | -0.82 | -0.79 | -0.77 | -2.72 |
| Average Basic Shares Outstanding | 3.12M | 3.12M | 1.34M | 1.34M | 850.30K |
| Average Diluted Shares Outstanding | 6.20K | 6.20K | 2.60K | 2.60K | 1.70K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |